Project Grant R43DA052947

This $2,370,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools to create comprehensive, region-specific models for studying pain circuitry. The award to Trustees of Tufts College (Tufts University) supports three main objectives: 1) Developing scalable methods to generate region-specific sensory neurons and...

This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding the generation and characterization of a novel NTRK3-FLPO knockin mouse line at the University of Pennsylvania. The goal is to enable specific genetic targeting and interrogation of A-beta nociceptors, an important but understudied subpopulation of somatosensory neurons, in order...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The 4-year project, starting on April 15, 2025, will characterize the genetic architecture underlying chronic pain liability and addiction, estimate...

This Project Grant award of $650,079 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop selective probes targeting the α9 nicotinic acetylcholine receptor (α9*-nAChR) for treating chronic inflammatory and neuropathic pain. The key objectives are to: 1) Develop small-molecule agonists and antagonists of α9*-nAChR through structure-activity...

This Cooperative Agreement award of $1,278,689 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop an automated Neonatal Pain Monitoring System (NPMS) and pain management protocol to objectively measure and minimize postoperative pain in newborns. The project has two key objectives: 1) Develop and validate AI-driven neonatal pain biomarker signatures and an automated NPMS to continuously...